🇺🇸 FDA
Patent

US 12121567

Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase

granted A61KA61K38/47A61K48/00

Quick answer

US patent 12121567 (Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase) held by Regents of the University of Minnesota expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K38/47, A61K48/00, A61P, A61P25/00